<<< WE ARE NOW HIRING! Join our team of clinical professionals today!


Blog Layout

IGC Pharma Announces First Patient Dosed at ClinCloud in Phase 2 Trial on Agitation in Alzheimer’s Disease


Jonathan Alicano • Feb 28, 2024

Unveiling Hope - A Breakthrough in Alzheimer’s Treatment

Trial to investigate efficacy of IGC-AD1 on agitation in Alzheimer’s Disease impacting 40-80% of patients


POTOMAC, Md., January XX, 2024 — IGC Pharma, Inc (NYSE American: IGC) (“IGC” or the “Company”), today announced that the first patient was dosed at the ClinCloud clinical research facility in Florida as part of the Company’s ongoing Phase 2 trial.


IGC Pharma is currently conducting a Phase 2 trial with IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties, and an inflammasome inhibitor to treat agitation in dementia from Alzheimer’s. Neuroinflammation, neurotransmitter imbalance, loss of CB1r, and inflammasome-3 have been implicated in agitation/aggression.


Unveiling Hope - A Breakthrough in Alzheimer’s Treatment

January 15, 2024


Today marks a significant stride in the pursuit of a breakthrough therapy for agitation in Alzheimer's disease as IGC Pharma proudly announces the initiation of its Phase 2 trial, with the first patient dosed at ClinCloud in Florida.


Agitation in Alzheimer’s is a challenging aspect affecting over 80% of patients and causing distress to both patients and their caregivers. IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties, and an inflammasome inhibitor, is at the forefront of innovative treatment strategies.


Jessica Branning, Founder at ClinCloud, commented, “Treatment options targeting agitation in Alzheimer’s disease are currently limited. This Phase 2 clinical trial aligns with ClinCloud’s mission to transform healthcare with continuous improvements and revolutionary breakthroughs. It’s more important than ever to identify treatments for neurodegenerative conditions.”


Ram Mukunda, CEO of IGC Pharma stated, “We are excited to announce this important milestone in the Phase 2 trial of IGC-AD1. This strategic move amplifies our reach and strengthens the depth of our data collection, marking a critical phase in our pursuit of a breakthrough therapy for agitation in Alzheimer's disease.”


IGC Pharma has 12 other sites under contract and is on target to roll out additional sites in the U.S. and in Canada to increase population diversity and promote the inclusion of underrepresented populations. The trial will enroll 146 patients with one half, the treated group, receiving IGC-AD1, and the other half, the control group, receiving a placebo.


About ClinCloud

ClinCloud Clinical Research (www.clincloudresearch.com) has 2 centers located in Melbourne and Maitland, Florida, with active clinical studies in Alzheimer’s disease, and other diseases.



Share This Post

By Jonathan Alicano 01 May, 2024
Phase II/III Trial Results Released: Progressing Toward Enhanced Therapies for Neurological Disorders
By Jonathan Alicano 01 Apr, 2024
 Understanding Memory Changes: Normal Aging vs. Alzheimer's Disease As we age, it's natural to experience changes in memory and cognitive function. However, distinguishing between typical age-related memory decline and more serious cognitive issues, such as Alzheimer's disease, can be crucial for early intervention and management. We spoke with Dr. Rosemary Laird, a specialist in memory care, to shed light on these differences and offer valuable insights for readers. Normal Aging: Recognizing Common Memory Changes "As people get older, a certain amount of forgetfulness can be expected," Dr. Laird explains. "Aging affects every bodily system, including the brain. It's common for individuals to notice a decrease in the speed of memory retrieval and an increased need for focused attention on tasks. While forgetfulness may occur occasionally, it typically does not lead to significant problems." Dr. Laird emphasizes, "However, it's important to recognize when memory lapses may indicate a more serious issue. For instance, occasional forgetfulness, such as momentarily misplacing car keys, is considered normal aging. In contrast, persistent memory lapses that interfere with daily functioning, like repeatedly forgetting where one parked the car, could be indicative of Alzheimer's disease." Alzheimer's Disease: Understanding the Differences "The key difference lies in the severity of the change in functioning brain tissue," says Dr. Laird. "Aging leads to reduced brain size, known as atrophy, which can result in reduced function. However, Alzheimer’s disease causes atrophy at markedly faster rates than aging alone, particularly in the memory and language centers." Certain risk factors and genetic predispositions may increase susceptibility to Alzheimer's disease: Age: Advanced age is the most significant risk factor for Alzheimer's disease. The likelihood of developing the condition increases with age, particularly after 65 years old. Family History and Genetics: Individuals with a family history of Alzheimer's disease are at higher risk of developing the disease. Certain genetic variations are associated with early-onset familial Alzheimer's disease. Down’s Syndrome: People with Down’s syndrome have an increased risk of developing Alzheimer's disease, typically at an earlier age than the general population. Cardiovascular Risk Factors: Conditions that affect cardiovascular health, such as hypertension, diabetes, obesity, and high cholesterol, have been linked to an increased risk of Alzheimer's disease. Traumatic Brain Injury (TBI): A history of moderate to severe traumatic brain injury, particularly repeated head injuries, may increase the risk of developing Alzheimer's disease later in life. Lifestyle Factors: Certain lifestyle factors, such as physical inactivity, poor diet, smoking, and limited social engagement, may contribute to an increased risk of Alzheimer's disease. Environmental Factors: Exposure to certain environmental toxins or pollutants may play a role in the development of Alzheimer's disease, although further research is needed to understand these associations fully. For further information on risk factors and genetic predispositions, individuals can explore resources such as the National Institute of Aging. Diagnosis and Assessment: Advances in Early Detection "In diagnosing Alzheimer's disease, significant advancements have been made," notes Dr. Laird. "It is crucial to undergo evaluation by a memory care specialist familiar with the full range of diagnostic testing available. It is no longer sufficient to attribute symptoms solely to age without thorough testing." Advancements in diagnostic tools have revolutionized the early detection of Alzheimer's disease. Now more than ever, it is important to see a memory care specialist This may include a thorough history of cognitive complaints, physical examinations, cognitive assessments, and advanced imaging techniques such as PET scans. Additionally, individuals concerned about their cognitive health are encouraged to undergo baseline cognitive assessments and explore strategies for risk reduction. Local resources such as Memory Disorder Clinics or research clinics like ClinCloud in Viera, where Dr. Laird is a Principal Investigator, can provide guidance and support for those seeking evaluation. Advice for Readers: Taking Proactive Steps "Two key steps include seeking evaluation and obtaining a baseline assessment of cognitive abilities," advises Dr. Laird. "Additionally, educating oneself about risks and strategies to mitigate them is essential." She recommends seeking medical evaluation, obtaining a baseline cognitive assessment, and learning about strategies to prevent Alzheimer's disease. About ClinCloud Research Explore cutting-edge medical research at ClinCloud, a premier institution conducting clinical trials for various conditions, including Alzheimer's disease, liver disease, diabetes, and more. With clinics conveniently located in Maitland and Viera, ClinCloud serves the broader central Florida community. For additional information, visit ClinCloudresearch.com or call (407) 636-4031.

By Global Alzheimer's Platform Foundation 28 Feb, 2024
Washington D.C., Feb. 28, 2024 - GAP releases groundbreaking findings from the Bio-Hermes-001 Study, revealing a strong link between blood biomarkers, like p-tau 217, and Alzheimer's brain plaques. The study, inclusive of diverse participants, promises faster, more accurate diagnoses and streamlined clinical trial enrollment. Co-authored by leading experts and supported by a coalition of partners, the study marks a significant step toward revolutionizing Alzheimer's care. For more information, visit https://doi.org/10.1002/alz.13722.
By Jonathan Alicano 02 Jan, 2024
Memory screens: A proactive measure for seniors, preserving precious memories and paving the way for a brighter future in cognitive well-being.
By Stephanie Jones 01 Nov, 2023
Clinical research studies play a pivotal role in advancing medical knowledge, developing new treatments, and improving healthcare outcomes.
By Stephanie Jones 01 Nov, 2023
Unveiling the Benefits of Liver FibroScan: A Vital Screening for Liver Health
By Sarah Schumaker 20 Apr, 2022
It doesn't normally pop into our heads to associate risk with a positive outcome, so why does 'risking it all' kind of sound exciting?
By Valery R Crespo-Matos 15 Apr, 2022
We all care for our physical health. For example, we visit the dentist every six months for oral cleaning or see our primary care physician for regular blood tests and general physical examination check-up. Women over the age of 40 get their annual mammograms, but when do we check our brains?
By Sarah Schumaker 21 Mar, 2022
With Spring comes blossoming fragrant flowers, but we must not forget what it took for them to get there...
By Sarah Schumaker 10 Mar, 2022
"Music and art can enrich the lives of people with Alzheimer's disease. Both allow for self-expression and engagement, even after dementia has progressed." -Alzheimer's Association
More Posts
Share by: